Search

Your search keyword '"Di Donato V"' showing total 465 results
Start Over Author "Di Donato V"
465 results on '"Di Donato V"'

1. First-Line Treatment  with Olaparib for Early Stage BRCA-Positive Ovarian Cancer: May It Be Possible? Hypothesis Potentially Generating a Line of Research

Author

Tomao F, Boccia SM, Sassu CM, Chirra M, Palaia I, Petrella MC, Di Donato V, Colombo N, and Benedetti Panici P

Subjects
newly diagnosed ovarian cancer, early stage ovarian cancer, olaparib, parpinhibitors, brca mutation., Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Federica Tomao,1 Serena Maria Boccia,2 Carolina Maria Sassu,2 Martina Chirra,3 Innocenza Palaia,2 Maria Cristina Petrella,4 Violante Di Donato,2 Nicoletta Colombo,1,5 Pierluigi Benedetti Panici2 1Department of Gynecologic Oncology, European Institute of Oncology (IEO) IRCCS, Milan, Italy; 2Department of Maternal and Child Health and Urological Sciences, “Sapienza” University of Rome,Polyclinic Umberto I, Rome, Italy; 3Medical Oncology Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy; 4Medical Oncology, AOUC University Hospital Careggi, Florence, Italy; 5Department of Medicine and Surgery, University of Milan-Bicocca, Milan, ItalyCorrespondence: Carolina Maria SassuDepartment of Maternal and Child Health and Urological Sciences, “Sapienza” University of Rome, Polyclinic Umberto I, Viale Del Policlinico 155, Rome 00161, ItalyTel +393935691077Fax +390649972564Email carolinamaria.sassu@uniroma1.itAbstract: Olaparib is currently approved in maintenance treatment of advanced ovarian cancer after response to first-line chemotherapy for breast related cancer antigens (BRCA) mutated patients. The use of this agent is based on data from SOLO1 study that observed a decreased risk of disease progression or death and a median progression-free survival about 36 months longer in case of therapy with olaparib. However, this trial recruited only patients with advanced stage ovarian cancer. The aim of this review is to retrace the available data in order to clarify the potential efficacy and feasibility of olaparib administration in newly diagnosed epithelial ovarian cancer also in early stages.Keywords: newly diagnosed ovarian cancer, early stage ovarian cancer, olaparib, PARPinhibitors, BRCA mutation

Published
2020

2. Vulvar lipoma: rare case, rare location

Author

Cuccu, I., primary, Golia D’Augè, T., additional, Di Dio, C., additional, Giannini, A., additional, Laganà, A.S., additional, Chiantera, V., additional, Bogani, G., additional, Pernazza, A., additional, Manganaro, L., additional, Miceli, V., additional, Santangelo, G., additional, Muzii, L., additional, Di Donato, V., additional, and Perniola, G., additional

Published
2024
Full Text
View/download PDF

3. Management of primary and recurrent Bartholin’s gland carcinoma: A systematic review on behalf of MITO Rare Cancer Group

Author

Turetta, C, Mazzeo, R, Capalbo, G, Miano, S, Fruscio, R, Di Donato, V, Falcone, F, Mangili, G, Pignata, S, Palaia, I, Turetta C., Mazzeo R., Capalbo G., Miano S., Fruscio R., Di Donato V., Falcone F., Mangili G., Pignata S., Palaia I., Turetta, C, Mazzeo, R, Capalbo, G, Miano, S, Fruscio, R, Di Donato, V, Falcone, F, Mangili, G, Pignata, S, Palaia, I, Turetta C., Mazzeo R., Capalbo G., Miano S., Fruscio R., Di Donato V., Falcone F., Mangili G., Pignata S., and Palaia I.

Abstract

Bartholin gland carcinoma is an extremely rare disease. Information regarding treatment is scarce and there is no strict consensus on best practice. All studies reporting cases of Bartholin’s gland cancer were screened and evaluated for inclusion. Baseline characteristics of studies were extracted. A total number of 290 manuscripts collected were available for the review process. Studies included in a previous systematic review were not duplicated. In total, details of 367 patients were collected, as follows: histological features, clinical presentation, treatment, recurrent rate, treatment of recurrence and outcome. About 35% of Bartholin gland carcinoma were squamous cell carcinoma. Almost 50% of patients presented with advanced stage. The therapeutic approach was mainly surgery, and in 61% of those women lymph node assessment was performed. Recurrence occurred in 21% of cases. Bartholin gland cancer remains a challenge for gynecologic oncologists. Guidelines, centralization to referral centers and standardized therapy are needed.

Published
2023

4. Hysterectomy alone vs. hysterectomy plus sentinel node mapping in endometrial cancer: Perioperative and long-term results from a propensity-score based study

Author

Bogani, G, Di Donato, V, Papadia, A, Buda, A, Casarin, J, Multinu, F, Plotti, F, Gasparri, M, Pinelli, C, Perrone, A, Ferrero, S, Sorbi, F, Landoni, F, Palaia, I, Perniola, G, De Iaco, P, Cianci, S, Alletti, S, Petrillo, M, Vizzielli, G, Fanfani, F, Angioli, R, Muzii, L, Ghezzi, F, Vizza, E, Mueller, M, Scambia, G, Panici, P, Raspagliesi, F, Bogani G., Di Donato V., Papadia A., Buda A., Casarin J., Multinu F., Plotti F., Gasparri M. L., Pinelli C., Perrone A. M., Ferrero S., Sorbi F., Landoni F., Palaia I., Perniola G., De Iaco P., Cianci S., Alletti S. G., Petrillo M., Vizzielli G., Fanfani F., Angioli R., Muzii L., Ghezzi F., Vizza E., Mueller M. D., Scambia G., Panici P. B., Raspagliesi F., Bogani, G, Di Donato, V, Papadia, A, Buda, A, Casarin, J, Multinu, F, Plotti, F, Gasparri, M, Pinelli, C, Perrone, A, Ferrero, S, Sorbi, F, Landoni, F, Palaia, I, Perniola, G, De Iaco, P, Cianci, S, Alletti, S, Petrillo, M, Vizzielli, G, Fanfani, F, Angioli, R, Muzii, L, Ghezzi, F, Vizza, E, Mueller, M, Scambia, G, Panici, P, Raspagliesi, F, Bogani G., Di Donato V., Papadia A., Buda A., Casarin J., Multinu F., Plotti F., Gasparri M. L., Pinelli C., Perrone A. M., Ferrero S., Sorbi F., Landoni F., Palaia I., Perniola G., De Iaco P., Cianci S., Alletti S. G., Petrillo M., Vizzielli G., Fanfani F., Angioli R., Muzii L., Ghezzi F., Vizza E., Mueller M. D., Scambia G., Panici P. B., and Raspagliesi F.

Abstract

Objective: To compare outcomes after hysterectomy and hysterectomy plus sentinel node mapping (SNM) in endometrial cancer (EC) patients. Materials and methods: This is a retrospective study, collecting data of EC patients treated between 2006 and 2016 in nine referral centers. Results: The study population included 398 (69.5%) and 174 (30.5%) patients having hysterectomy and hysterectomy plus SNM. As the results of the adoption of a propensity-score matched analysis, we selected two homogeneous cohort of patients (150 having hysterectomy only vs. 150 having hysterectomy plus SNM). The SNM group had a longer operative time, but did not correlate with length of hospital stay and estimated blood loss. Overall severe complication rates were similar between groups (0.7% in the hysterectomy group vs. 1.3% in the hysterectomy plus SNM group; p = 0.561). No lymphatic-specific complication occurred. Overall, 12.6% of patients having SNM were diagnosed with disease harboring in their lymph nodes. Adjuvant therapy administration rate was similar between groups. Considering patients having SNM, 4% of patients received adjuvant therapy on the basis of nodal status alone; all the other patients received adjuvant therapy also on the basis of uterine risk factors. Five-year disease-free (p = 0.720) and overall (p = 0.632) survival was not influenced by surgical approach. Conclusions: Hysterectomy (with or without SNM) is a safe and effective method for managing EC patients. Potentially, these data support the omission of side specific lymphadenectomy in case of unsuccessful mapping. Further evidence is warranted in to confirm the role SNM in the era of molecular/genomic profiling.

Published
2023

7. P22-14: Towards developing a harmonized experimental protocol of embryonic zebrafish light/dark transition behavior test for Organisation for Economic Co-operation and Development (OECD) Developmental Neurotoxicity (DNT) In-Vitro Testing Battery

Author

Sanz, C. Miguel, primary, Schiavone, V., additional, Ibarra, J., additional, Di Donato, V., additional, Truong, L., additional, Tanguay, R., additional, Hsieh, J.-H., additional, Ryan, K., additional, Ellis, L., additional, Martinez, B. Molina, additional, Del Pozo, A., additional, Alzualde, A., additional, Muriana, A., additional, Kluver, N., additional, Behl, M., additional, Woodland, C., additional, Sachana, M., additional, and Hessel, E., additional

Published
2023
Full Text
View/download PDF

10. Clear cell carcinoma of the endometrium

Author

Bogani, G, Ray-Coquard, I, Concin, N, Ngoi, N, Morice, P, Enomoto, T, Takehara, K, Denys, H, Lorusso, D, Coleman, R, Vaughan, M, Takano, M, Provencher, D, Sagae, S, Wimberger, P, Poka, R, Segev, Y, Kim, S, Kim, J, Candido dos Reis, F, Mariani, A, Leitao, M, Makker, V, Rustum, N, Vergote, I, Zannoni, G, Tan, D, Mccormack, M, Bini, M, Lopez, S, Raspagliesi, F, Panici, P, di Donato, V, Muzii, L, Colombo, N, Scambia, G, Pignata, S, Monk, B, Bogani G., Ray-Coquard I., Concin N., Ngoi N. Y. L., Morice P., Enomoto T., Takehara K., Denys H., Lorusso D., Coleman R., Vaughan M. M., Takano M., Provencher D., Sagae S., Wimberger P., Poka R., Segev Y., Kim S. I., Kim J. -W., Candido dos Reis F. J., Mariani A., Leitao M. M., Makker V., Rustum N. A., Vergote I., Zannoni G. F., Tan D. S. P., McCormack M., Bini M., Lopez S., Raspagliesi F., Panici P. B., di Donato V., Muzii L., Colombo N., Scambia G., Pignata S., Monk B. J., Bogani, G, Ray-Coquard, I, Concin, N, Ngoi, N, Morice, P, Enomoto, T, Takehara, K, Denys, H, Lorusso, D, Coleman, R, Vaughan, M, Takano, M, Provencher, D, Sagae, S, Wimberger, P, Poka, R, Segev, Y, Kim, S, Kim, J, Candido dos Reis, F, Mariani, A, Leitao, M, Makker, V, Rustum, N, Vergote, I, Zannoni, G, Tan, D, Mccormack, M, Bini, M, Lopez, S, Raspagliesi, F, Panici, P, di Donato, V, Muzii, L, Colombo, N, Scambia, G, Pignata, S, Monk, B, Bogani G., Ray-Coquard I., Concin N., Ngoi N. Y. L., Morice P., Enomoto T., Takehara K., Denys H., Lorusso D., Coleman R., Vaughan M. M., Takano M., Provencher D., Sagae S., Wimberger P., Poka R., Segev Y., Kim S. I., Kim J. -W., Candido dos Reis F. J., Mariani A., Leitao M. M., Makker V., Rustum N. A., Vergote I., Zannoni G. F., Tan D. S. P., McCormack M., Bini M., Lopez S., Raspagliesi F., Panici P. B., di Donato V., Muzii L., Colombo N., Scambia G., Pignata S., and Monk B. J.

Abstract

Clear cell endometrial carcinoma represents an uncommon and poorly understood entity. Data from molecular/genomic profiling highlighted the importance of various signatures in assessing the prognosis of endometrial cancer according to four classes of risk (POLE mutated, MMRd, NSMP, and p53 abnormal). Unfortunately, data specific to clear cell histological subtype endometrial cancer are lacking. More recently, data has emerged to suggest that most of the patients (more than 80%) with clear cell endometrial carcinoma are characterized by p53 abnormality or NSMP type. This classification has important therapeutic implications. Although it is an uncommon entity, clear cell endometrial cancer patients with POLE mutation seem characterized by a good prognosis. Chemotherapy is effective in patients with NSMP (especially in stage III and IV) and patients with p53 abnormal disease (all stages). While, preliminary data suggested that patients with MMRd are less likely to benefit from chemotherapy. The latter group appears to benefit much more from immune checkpoint inhibitors: recent data from clinical trials on pembrolizumab plus lenvatinib and nivolumab plus cabozantinib supported that immunotherapy plus tyrosine kinase inhibitors (TKI) would be the most appropriate treatment for recurrent non-endometrioid endometrial cancer (including clear cell carcinoma) after the failure of platinum-based chemotherapy. Moreover, ongoing clinical trials testing the anti-tumor activity of innovative products will clarify the better strategies for advanced/recurrent clear cell endometrial carcinoma. Further prospective evidence is urgently needed to better characterize clear cell endometrial carcinoma.

Published
2022

11. MRI- and Histologic-Molecular-Based Radio-Genomics Nomogram for Preoperative Assessment of Risk Classes in Endometrial Cancer

Author

Celli, V, Guerreri, M, Pernazza, A, Cuccu, I, Palaia, I, Tomao, F, Di Donato, V, Pricolo, P, Ercolani, G, Ciulla, S, Colombo, N, Leopizzi, M, Di Maio, V, Faiella, E, Santucci, D, Soda, P, Cordelli, E, Perniola, G, Gui, B, Rizzo, S, Della Rocca, C, Petralia, G, Catalano, C, Manganaro, L, Celli V., Guerreri M., Pernazza A., Cuccu I., Palaia I., Tomao F., Di Donato V., Pricolo P., Ercolani G., Ciulla S., Colombo N., Leopizzi M., Di Maio V., Faiella E., Santucci D., Soda P., Cordelli E., Perniola G., Gui B., Rizzo S., Della Rocca C., Petralia G., Catalano C., Manganaro L., Celli, V, Guerreri, M, Pernazza, A, Cuccu, I, Palaia, I, Tomao, F, Di Donato, V, Pricolo, P, Ercolani, G, Ciulla, S, Colombo, N, Leopizzi, M, Di Maio, V, Faiella, E, Santucci, D, Soda, P, Cordelli, E, Perniola, G, Gui, B, Rizzo, S, Della Rocca, C, Petralia, G, Catalano, C, Manganaro, L, Celli V., Guerreri M., Pernazza A., Cuccu I., Palaia I., Tomao F., Di Donato V., Pricolo P., Ercolani G., Ciulla S., Colombo N., Leopizzi M., Di Maio V., Faiella E., Santucci D., Soda P., Cordelli E., Perniola G., Gui B., Rizzo S., Della Rocca C., Petralia G., Catalano C., and Manganaro L.

Abstract

High- and low-risk endometrial carcinoma (EC) differ in whether or not a lymphadenectomy is performed. We aimed to develop MRI-based radio-genomic models able to preoperatively assess lymph-vascular space invasion (LVSI) and discriminate between low- and high-risk EC according to the ESMO-ESGO-ESTRO 2020 guidelines, which include molecular risk classification proposed by “ProMisE”. This is a retrospective, multicentric study that included 64 women with EC who underwent 3T-MRI before a hysterectomy. Radiomics features were extracted from T2WI images and apparent diffusion coefficient maps (ADC) after manual segmentation of the gross tumor volume. We constructed a multiple logistic regression approach from the most relevant radiomic features to distinguish between low- and high-risk classes under the ESMO-ESGO-ESTRO 2020 guidelines. A similar approach was taken to assess LVSI. Model diagnostic performance was assessed via ROC curves, accuracy, sensitivity and specificity on training and test sets. The LVSI predictive model used a single feature from ADC as a predictor; the risk class model used two features as predictors from both ADC and T2WI. The low-risk predictive model showed an AUC of 0.74 with an accuracy, sensitivity, and specificity of 0.74, 0.76, 0.94; the LVSI model showed an AUC of 0.59 with an accuracy, sensitivity, and specificity of 0.60, 0.50, 0.61. MRI-based radio-genomic models are useful for preoperative EC risk stratification and may facilitate therapeutic management.

Published
2022

12. Corrigendum to “Assessing the role of minimally invasive radical hysterectomy for early-stage cervical cancer” [Eur. J. Obstet. Gynecol. 275 (2022) 64–69, (S0301211522003797), (10.1016/j.ejogrb.2022.06.004)]

Author

Bogani G., Bogani, G, Di Donato, V, Muzii, L, Casarin, J, Ghezzi, F, Malzoni, M, Greggi, S, Landoni, F, Bazzurini, L, Zanagnolo, V, Multinu, F, Angioli, R, Plotti, F, Caruso, G, Fischetti, M, Ferrandina, G, Palaia, I, Benedetti Panici, P, Scambia, G, Raspagliesi, F, Bogani G., Di Donato V., Muzii L., Casarin J., Ghezzi F., Malzoni M., Greggi S., Landoni F., Bazzurini L., Zanagnolo V., Multinu F., Angioli R., Plotti F., Caruso G., Fischetti M., Ferrandina G., Palaia I., Benedetti Panici P., Scambia G., Raspagliesi F., Bogani G., Bogani, G, Di Donato, V, Muzii, L, Casarin, J, Ghezzi, F, Malzoni, M, Greggi, S, Landoni, F, Bazzurini, L, Zanagnolo, V, Multinu, F, Angioli, R, Plotti, F, Caruso, G, Fischetti, M, Ferrandina, G, Palaia, I, Benedetti Panici, P, Scambia, G, Raspagliesi, F, Bogani G., Di Donato V., Muzii L., Casarin J., Ghezzi F., Malzoni M., Greggi S., Landoni F., Bazzurini L., Zanagnolo V., Multinu F., Angioli R., Plotti F., Caruso G., Fischetti M., Ferrandina G., Palaia I., Benedetti Panici P., Scambia G., and Raspagliesi F.

Published
2022

13. Outcomes of High-Grade Cervical Dysplasia with Positive Margins and HPV Persistence after Cervical Conization

Author

Giannini, A., Di Donato, V., Sopracordevole, F., Ciavattini, A., Ghelardi, A., Vizza, E., D’Oria, O., Simoncini, T., Plotti, F., Casarin, J., Golia D’Augè, T., Cuccu, I., Serati, M., Pinelli, C., Bergamini, A., Gardella, B., Dell’Acqua, A., Monti, E., Vercellini, P., D’Ippolito, G., Aguzzoli, L., Dario Mandato, V., Giannella, L., Scaffa, C., Ditto, A., Falcone, F., Borghi, C., Malzoni, M., Di Giovanni, A., Salerno, M. G., Liberale, V., Contino, B., Donfrancesco, C., Desiato, M., Perrone, A. M., De Iaco, P., Ferrero, S., Sarpietro, G., Matarazzo, M. G., Cianci, A., Cianci, S., Bosio, S., Ruisi, S., Mosca, L., Tinelli, R., De Vincenzo, Rosa Pasqualina, Zannoni, Gian Franco, Ferrandina, Maria Gabriella, Petrillo, M., Capobianco, G., Carlea, A., Zullo, F., Muschiato, B., Palomba, S., Greggi, S., Spinillo, A., Ghezzi, F., Colacurci, N., Angioli, R., Benedetti Panici, P., Muzii, L., Scambia, Giovanni, Raspagliesi, F., Bogani, G., De Vincenzo R. (ORCID:0000-0001-7408-0435), Zannoni G. F. (ORCID:0000-0003-1809-129X), Ferrandina G. (ORCID:0000-0003-4672-4197), Scambia G. (ORCID:0000-0003-2758-1063), Giannini, A., Di Donato, V., Sopracordevole, F., Ciavattini, A., Ghelardi, A., Vizza, E., D’Oria, O., Simoncini, T., Plotti, F., Casarin, J., Golia D’Augè, T., Cuccu, I., Serati, M., Pinelli, C., Bergamini, A., Gardella, B., Dell’Acqua, A., Monti, E., Vercellini, P., D’Ippolito, G., Aguzzoli, L., Dario Mandato, V., Giannella, L., Scaffa, C., Ditto, A., Falcone, F., Borghi, C., Malzoni, M., Di Giovanni, A., Salerno, M. G., Liberale, V., Contino, B., Donfrancesco, C., Desiato, M., Perrone, A. M., De Iaco, P., Ferrero, S., Sarpietro, G., Matarazzo, M. G., Cianci, A., Cianci, S., Bosio, S., Ruisi, S., Mosca, L., Tinelli, R., De Vincenzo, Rosa Pasqualina, Zannoni, Gian Franco, Ferrandina, Maria Gabriella, Petrillo, M., Capobianco, G., Carlea, A., Zullo, F., Muschiato, B., Palomba, S., Greggi, S., Spinillo, A., Ghezzi, F., Colacurci, N., Angioli, R., Benedetti Panici, P., Muzii, L., Scambia, Giovanni, Raspagliesi, F., Bogani, G., De Vincenzo R. (ORCID:0000-0001-7408-0435), Zannoni G. F. (ORCID:0000-0003-1809-129X), Ferrandina G. (ORCID:0000-0003-4672-4197), and Scambia G. (ORCID:0000-0003-2758-1063)

Abstract

The objective of this work is to assess the 5-year outcomes of patients undergoing conization for high-grade cervical lesions that simultaneously present as risk factors in the persistence of HPV infection and the positivity of surgical resection margins. This is a retrospective study evaluating patients undergoing conization for high-grade cervical lesions. All patients included had both positive surgical margins and experienced HPV persistence at 6 months. Associations were evaluated with Cox proportional hazard regression and summarized using hazard ratio (HR). The charts of 2966 patients undergoing conization were reviewed. Among the whole population, 163 (5.5%) patients met the inclusion criteria, being at high risk due to the presence of positive surgical margins and experiencing HPV persistence. Of 163 patients included, 17 (10.4%) patients developed a CIN2+ recurrence during the 5-year follow-up. Via univariate analyses, diagnosis of CIN3 instead of CIN2 (HR: 4.88 (95%CI: 1.10, 12.41); p = 0.035) and positive endocervical instead of ectocervical margins (HR: 6.44 (95%CI: 2.80, 9.65); p < 0.001) were associated with increased risk of persistence/recurrence. Via multivariate analyses, only positive endocervical instead of ectocervical margins (HR: 4.56 (95%CI: 1.23, 7.95); p = 0.021) were associated with worse outcomes. In this high-risk group, positive endocervical margins is the main risk factor predicting 5-year recurrence.

Published
2023

14. The role of immunotherapy in advanced and recurrent MMR deficient and proficient endometrial carcinoma

Author

Di Dio, C., Bogani, G., Di Donato, V., Cuccu, I., Muzii, L., Musacchio, L., Scambia, Giovanni, Lorusso, Domenica, Scambia G. (ORCID:0000-0003-2758-1063), Lorusso D., Di Dio, C., Bogani, G., Di Donato, V., Cuccu, I., Muzii, L., Musacchio, L., Scambia, Giovanni, Lorusso, Domenica, Scambia G. (ORCID:0000-0003-2758-1063), and Lorusso D.

Abstract

Endometrial cancer is the most common gynecological disease in developed countries. Although it is considered an indolent disease, advanced and recurrent endometrial carcinomas are characterized by poor prognosis. In the metastatic setting, after the failure of first-line platinum-based chemotherapy, patients have limited therapeutic options. However, endometrial cancer should not be considered as a single entity but as a group of heterogeneous diseases with specific genomic, molecular, and biological features by suggested the analysis of The Cancer Genome Atlas (TCGA). Accumulating data highlighted the effectiveness and safety of the adoption of immune checkpoint inhibitors (ICIs) for several types of solid tumors. In particular, immunotherapy showed promising results in MSI-H/dMMR solid tumors. Endometrial cancer is not an exception. Endometrial cancer has the highest prevalence of MSI across human cancer types, and approximately 30% of primary endometrial cancers are MSI-H/dMMR and 13% to 30% of recurrent endometrial cancers are MSI-H/dMMR. The preliminary results of the KEYNOTE-158, the Australian NCT03015129 and the GARNET trial strongly supported the adoption of ICIs as monotherapy in patients with advanced or recurrent endometrial cancer, after the failure of first-line treatments. Unfortunately, those impressive results are not achieved in patients with MMR proficient disease. Hence, other combinations were tested. In particular, the adoption of ICIs plus tyrosine kinase inhibitors (TKI) showed very compelling results. Recently, the updated results of the KEYNOTE-775 showed that pembrolizumab plus lenvatinib led to significantly longer progression-free and overall survival than chemotherapy among patients with advanced endometrial cancer, irrespective of MMR status. After EMA approval, pembrolizumab plus lenvatinib represents the new standard second-line treatment in endometrial cancer patients, regardless MMR status. Further studies are investigating the ro

Published
2023

15. Towards developing a harmonized experimental protocol of embryonic zebrafish light/dark transition behavior test for Organisation for Economic Co-operation and Development (OECD) Developmental Neurotoxicity (DNT) In-Vitro Testing Battery

Author

Sanz, C.M., Schiavone, V., Ibarra, J., Di Donato, V., Truong, L., Tanguay, R., Hsieh, J.-H., Ryan, K., Ellis, L., Molina Martinez, B., Del Pozo, A., Alzualde, A., Muriana, A., Klüver, Nils, Behl, M., Woodland, C., Sachana, M., Hessel, E., Sanz, C.M., Schiavone, V., Ibarra, J., Di Donato, V., Truong, L., Tanguay, R., Hsieh, J.-H., Ryan, K., Ellis, L., Molina Martinez, B., Del Pozo, A., Alzualde, A., Muriana, A., Klüver, Nils, Behl, M., Woodland, C., Sachana, M., and Hessel, E.

Abstract

no abstract

Published
2023

16. Endometrial carcinosarcoma

Author

Bogani, G, Ray-Coquard, I, Concin, N, Ngoi, N, Morice, P, Caruso, G, Enomoto, T, Takehara, K, Denys, H, Lorusso, D, Coleman, R, Vaughan, M, Takano, M, Provencher, D, Sagae, S, Wimberger, P, Póka, R, Segev, Y, Kim, S, Kim, J, Candido Dos Reis, F, Ramirez, P, Mariani, A, Leitao, M, Makker, V, Abu-Rustum, N, Vergote, I, Zannoni, G, Tan, D, Mccormack, M, Paolini, B, Bini, M, Raspagliesi, F, Benedetti Panici, P, Di Donato, V, Muzii, L, Colombo, N, Pignata, S, Scambia, G, Monk, B, Bogani, Giorgio, Ray-Coquard, Isabelle, Concin, Nicole, Ngoi, Natalie Yan Li, Morice, Philippe, Caruso, Giuseppe, Enomoto, Takayuki, Takehara, Kazuhiro, Denys, Hannelore, Lorusso, Domenica, Coleman, Robert, Vaughan, Michelle M, Takano, Masashi, Provencher, Diane Michele, Sagae, Satoru, Wimberger, Pauline, Póka, Robert, Segev, Yakir, Kim, Se Ik, Kim, Jae-Weon, Candido Dos Reis, Francisco Jose, Ramirez, Pedro T, Mariani, Andrea, Leitao, Mario, Makker, Vicky, Abu-Rustum, Nadeem R, Vergote, Ignace, Zannoni, Gianfranco, Tan, David, McCormack, Mary, Paolini, Biagio, Bini, Marta, Raspagliesi, Francesco, Benedetti Panici, Pierluigi, Di Donato, Violante, Muzii, Ludovico, Colombo, Nicoletta, Pignata, Sandro, Scambia, Giovanni, Monk, Bradley J, Bogani, G, Ray-Coquard, I, Concin, N, Ngoi, N, Morice, P, Caruso, G, Enomoto, T, Takehara, K, Denys, H, Lorusso, D, Coleman, R, Vaughan, M, Takano, M, Provencher, D, Sagae, S, Wimberger, P, Póka, R, Segev, Y, Kim, S, Kim, J, Candido Dos Reis, F, Ramirez, P, Mariani, A, Leitao, M, Makker, V, Abu-Rustum, N, Vergote, I, Zannoni, G, Tan, D, Mccormack, M, Paolini, B, Bini, M, Raspagliesi, F, Benedetti Panici, P, Di Donato, V, Muzii, L, Colombo, N, Pignata, S, Scambia, G, Monk, B, Bogani, Giorgio, Ray-Coquard, Isabelle, Concin, Nicole, Ngoi, Natalie Yan Li, Morice, Philippe, Caruso, Giuseppe, Enomoto, Takayuki, Takehara, Kazuhiro, Denys, Hannelore, Lorusso, Domenica, Coleman, Robert, Vaughan, Michelle M, Takano, Masashi, Provencher, Diane Michele, Sagae, Satoru, Wimberger, Pauline, Póka, Robert, Segev, Yakir, Kim, Se Ik, Kim, Jae-Weon, Candido Dos Reis, Francisco Jose, Ramirez, Pedro T, Mariani, Andrea, Leitao, Mario, Makker, Vicky, Abu-Rustum, Nadeem R, Vergote, Ignace, Zannoni, Gianfranco, Tan, David, McCormack, Mary, Paolini, Biagio, Bini, Marta, Raspagliesi, Francesco, Benedetti Panici, Pierluigi, Di Donato, Violante, Muzii, Ludovico, Colombo, Nicoletta, Pignata, Sandro, Scambia, Giovanni, and Monk, Bradley J

Abstract

Endometrial carcinosarcoma is a rare and aggressive high-grade endometrial carcinoma with secondary sarcomatous trans-differentiation (conversion theory). The clinical presentation and diagnostic work-up roughly align with those of the more common endometrioid counterpart, although endometrial carcinosarcoma is more frequently diagnosed at an advanced stage. Endometrial carcinosarcoma is not a single entity but encompasses different histological subtypes, depending on the type of carcinomatous and sarcomatous elements. The majority of endometrial carcinosarcomas are characterized by p53 abnormalities. The proportion of POLE and microsatellite instablity-high (MSI-H) is directly related to the epithelial component, being approximately 25% and 3% in endometrioid and non-endometrioid components.The management of non-metastatic disease is based on a multimodal approach with optimal surgery followed by (concomitant or sequential) chemotherapy and radiotherapy, even for early stages. Palliative chemotherapy is recommended in the metastatic or recurrent setting, with carboplatin/paclitaxel doublet being the first-line regimen. Although the introduction of immunotherapy plus/minus a tyrosine kinase inhibitor shifted the paradigm of treatment of patients with recurrent endometrial cancer, patients with endometrial carcinosarcoma were excluded from most studies evaluating single-agent immunotherapy or the combination. However, the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) approved the use of pembrolizumab and lenvatinib in endometrial cancer (all histotypes) after progression on chemotherapy and single-agent immunotherapy in MSI-H cancers. In the era of precision medicine, emerging knowledge on molecular endometrial carcinosarcoma is opening new promising therapeutic options for more personalized treatment. The present review outlines state-of-the-art knowledge and future directions for patients with endometrial carcinosarcoma.

Published
2023

23. Hysterectomy Alone vs. Hysterectomy Plus Sentinel Node Mapping in Endometrial Cancer: Long-Term Results from a Multi-Institutional Study

Author

Bogani, G., primary, Papadia, A., additional, Casarin, J., additional, Buda, A., additional, Multinu, F., additional, Plotti, F., additional, Perrone, A.M., additional, De Iaco, P., additional, Ghezzi, F., additional, Ferrero, S., additional, Angioli, R., additional, Muzii, L., additional, Landoni, F., additional, Mueller, M.D., additional, Benedetti Panici, P., additional, Raspagliesi, F., additional, and di Donato, V., additional

Published
2022
Full Text
View/download PDF

24. Three Lymphadenectomy Strategies in Endometrial Carcinoma: Analysis of Long-Term Outcomes

Author

Bogani, G., primary, di Donato, V., additional, Casarin, J., additional, Plotti, F., additional, Papadia, A., additional, Buda, A., additional, Multinu, F., additional, Perrone, A.M., additional, De Iaco, P., additional, Gasparri, M.L., additional, Ghezzi, F., additional, Ferrero, S., additional, Sorbi, F., additional, Angioli, R., additional, Landoni, F., additional, Mueller, M.D., additional, Muzii, L., additional, Benedetti Panici, P., additional, and Raspagliesi, F., additional

Published
2022
Full Text
View/download PDF

26. P17-22 Zebrafish, a novel key player for human risk assessment: latest advances on developmental neurotoxicity from an international consortium

Author

Sanz, C. Miguel, primary, Ibarra, J., additional, Rubbini, D., additional, Hsieh, J.-H., additional, Ellis, L., additional, Alzualde, A., additional, Truong, L., additional, Kluver, N., additional, Muriana, A., additional, Ryan, K., additional, Behl, M., additional, Molina, B., additional, Legradi, J., additional, Padilla, S., additional, Woodland, C., additional, Tanguay, R., additional, Hill, B., additional, Shafer, T., additional, Sachana, M., additional, Terriente, J., additional, Di Donato, V., additional, Schiavone, V., additional, and Hessel, E., additional

Published
2022
Full Text
View/download PDF

27. Factors predicting morbidity in surgically-staged high-risk endometrial cancer patients

Author

Bogani, G, Papadia, A, Buda, A, Casarin, J, Di Donato, V, Plotti, F, Gasparri, M, Cimmino, C, Pinelli, C, Perrone, A, Barra, F, Cromi, A, Di Martino, G, Palaia, I, Ferrero, S, Indini, A, De Iaco, P, Angioli, R, Luvero, D, Muzii, L, Ghezzi, F, Landoni, F, Mueller, M, Benedetti Panici, P, Raspagliesi, F, Bogani G., Papadia A., Buda A., Casarin J., Di Donato V., Plotti F., Gasparri M. L., Cimmino C., Pinelli C., Perrone A. M., Barra F., Cromi A., Di Martino G., Palaia I., Ferrero S., Indini A., De Iaco P., Angioli R., Luvero D., Muzii L., Ghezzi F., Landoni F., Mueller M. D., Benedetti Panici P., Raspagliesi F., Bogani, G, Papadia, A, Buda, A, Casarin, J, Di Donato, V, Plotti, F, Gasparri, M, Cimmino, C, Pinelli, C, Perrone, A, Barra, F, Cromi, A, Di Martino, G, Palaia, I, Ferrero, S, Indini, A, De Iaco, P, Angioli, R, Luvero, D, Muzii, L, Ghezzi, F, Landoni, F, Mueller, M, Benedetti Panici, P, Raspagliesi, F, Bogani G., Papadia A., Buda A., Casarin J., Di Donato V., Plotti F., Gasparri M. L., Cimmino C., Pinelli C., Perrone A. M., Barra F., Cromi A., Di Martino G., Palaia I., Ferrero S., Indini A., De Iaco P., Angioli R., Luvero D., Muzii L., Ghezzi F., Landoni F., Mueller M. D., Benedetti Panici P., and Raspagliesi F.

Abstract

Objective: To investigate factors predicting the risk of developing 90-day postoperative complications and lymphatic-specific morbidity in patients undergoing surgical staging for high-risk endometrial cancer. Methods: This is a multi-institutional retrospective cohort study. Patients affected by apparent early-stage high-risk endometrial cancer (endometrioid FIGO grade 3 with deep myometrial invasion and non-endometrioid endometrial cancer) undergoing surgical staging between 2007 and 2019. Complications were graded according to the Clavien-Dindo classification system. Martin criteria were applied to improve quality of complications reporting. Results: Charts of 279 patients were evaluated. Lymphadenectomy, sentinel node mapping (SNM), and SNM followed by back-up lymphadenectomy were performed in 83 (29.7%), 50 (17.9%), and 146 (52.4%) patients, respectively. The former group of patients included 13 patients who had lymphadenectomy after the failure of the SNM technique. Thirteen (4.6%) patients developed severe postoperative events (grade 3 or worse). At multivariate analysis, body mass index (OR: 1.08 (95%CI: 1.01, 1.17)) and open abdominal surgery (OR: 2.27 (95%CI: 1.02, 5.32)) were the two independent factors predictive of surgery-related morbidity. Seven severe lymphatic complications occurred. The adoption of laparoscopic approach (p < 0.001, log-rank test) and SNM (p = 0.038, log-rank test) correlated with a lower risk of developing surgery-related events. Independently, open abdominal surgery was associated with an increased risk of developing lymphatic morbidity (OR: 37.4 (95%CI: 4.38, 319.5); p = 0.001). Conclusion: The adoption of the laparoscopic approach and SNM technique were associated with lower 90-day complication rates than open surgery in high-risk endometrial cancer undergoing staging surgery.

Published
2021

28. Uterine serous carcinoma

Author

Bogani, G, Ray-Coquard, I, Concin, N, Ngoi, N, Morice, P, Enomoto, T, Takehara, K, Denys, H, Nout, R, Lorusso, D, Vaughan, M, Bini, M, Takano, M, Provencher, D, Indini, A, Sagae, S, Wimberger, P, Poka, R, Segev, Y, Kim, S, Candido dos Reis, F, Lopez, S, Mariani, A, Leitao, M, Raspagliesi, F, Panici, P, Di Donato, V, Muzii, L, Colombo, N, Scambia, G, Pignata, S, Monk, B, Bogani G., Ray-Coquard I., Concin N., Ngoi N. Y. L., Morice P., Enomoto T., Takehara K., Denys H., Nout R. A., Lorusso D., Vaughan M. M., Bini M., Takano M., Provencher D., Indini A., Sagae S., Wimberger P., Poka R., Segev Y., Kim S. I., Candido dos Reis F. J., Lopez S., Mariani A., Leitao M. M., Raspagliesi F., Panici P. B., Di Donato V., Muzii L., Colombo N., Scambia G., Pignata S., Monk B. J., Bogani, G, Ray-Coquard, I, Concin, N, Ngoi, N, Morice, P, Enomoto, T, Takehara, K, Denys, H, Nout, R, Lorusso, D, Vaughan, M, Bini, M, Takano, M, Provencher, D, Indini, A, Sagae, S, Wimberger, P, Poka, R, Segev, Y, Kim, S, Candido dos Reis, F, Lopez, S, Mariani, A, Leitao, M, Raspagliesi, F, Panici, P, Di Donato, V, Muzii, L, Colombo, N, Scambia, G, Pignata, S, Monk, B, Bogani G., Ray-Coquard I., Concin N., Ngoi N. Y. L., Morice P., Enomoto T., Takehara K., Denys H., Nout R. A., Lorusso D., Vaughan M. M., Bini M., Takano M., Provencher D., Indini A., Sagae S., Wimberger P., Poka R., Segev Y., Kim S. I., Candido dos Reis F. J., Lopez S., Mariani A., Leitao M. M., Raspagliesi F., Panici P. B., Di Donato V., Muzii L., Colombo N., Scambia G., Pignata S., and Monk B. J.

Abstract

Serous endometrial cancer represents a relative rare entity accounting for about 10% of all diagnosed endometrial cancer, but it is responsible for 40% of endometrial cancer-related deaths. Patients with serous endometrial cancer are often diagnosed at earlier disease stage, but remain at higher risk of recurrence and poorer prognosis when compared stage-for-stage with endometrioid subtype endometrial cancer. Serous endometrial cancers are characterized by marked nuclear atypia and abnormal p53 staining in immunohistochemistry. The mainstay of treatment for newly diagnosed serous endometrial cancer includes a multi-modal therapy with surgery, chemotherapy and/or radiotherapy. Unfortunately, despite these efforts, survival outcomes still remain poor. Recently, The Cancer Genome Atlas (TCGA) Research Network classified all endometrial cancer types into four categories, of which, serous endometrial cancer mostly is found within the “copy number high” group. This group is characterized by the increased cell cycle deregulation (e.g., CCNE1, MYC, PPP2R1A, PIKCA, ERBB2 and CDKN2A) and TP53 mutations (90%). To date, the combination of pembrolizumab and lenvatinib is an effective treatment modality in second-line therapy, with a response rate of 50% in advanced/recurrent serous endometrial cancer. Owing to the unfavorable outcomes of serous endometrial cancer, clinical trials are a priority. At present, ongoing studies are testing novel combinations of various targeted and immunotherapeutic agents in newly diagnosed and advanced/recurrent endometrial cancer - an important strategy for serous endometrial cancer, whereby tumors are usually p53+ and pMMR, making response to PD-1 inhibitor monotherapy unlikely. Here, the rare tumor working group (including members from the European Society of Gynecologic Oncology (ESGO), Gynecologic Cancer Intergroup (GCIG), and Japanese Gynecologic Oncology Group (JGOG)), performed a narrative review reporting on the current landscape of serous

Published
2021

29. Sentinel node mapping vs. sentinel node mapping plus back-up lymphadenectomy in high-risk endometrial cancer patients: Results from a multi-institutional study

Author

Bogani, G, Papadia, A, Buda, A, Casarin, J, Di Donato, V, Gasparri, M, Plotti, F, Pinelli, C, Paderno, M, Lopez, S, Perrone, A, Barra, F, Guerrisi, R, Brusadelli, C, Cromi, A, Ferrari, D, Chiapp, V, Signorelli, M, Maggiore, U, Ditto, A, Palaia, I, Ferrero, S, De Iaco, P, Angioli, R, Panici, P, Ghezzi, F, Landoni, F, Mueller, M, Raspagliesi, F, Bogani G., Papadia A., Buda A., Casarin J., Di Donato V., Gasparri M. L., Plotti F., Pinelli C., Paderno M. C., Lopez S., Perrone A. M., Barra F., Guerrisi R., Brusadelli C., Cromi A., Ferrari D., Chiapp V., Signorelli M., Maggiore U. L. R., Ditto A., Palaia I., Ferrero S., De Iaco P., Angioli R., Panici P. B., Ghezzi F., Landoni F., Mueller M. D., Raspagliesi F., Bogani, G, Papadia, A, Buda, A, Casarin, J, Di Donato, V, Gasparri, M, Plotti, F, Pinelli, C, Paderno, M, Lopez, S, Perrone, A, Barra, F, Guerrisi, R, Brusadelli, C, Cromi, A, Ferrari, D, Chiapp, V, Signorelli, M, Maggiore, U, Ditto, A, Palaia, I, Ferrero, S, De Iaco, P, Angioli, R, Panici, P, Ghezzi, F, Landoni, F, Mueller, M, Raspagliesi, F, Bogani G., Papadia A., Buda A., Casarin J., Di Donato V., Gasparri M. L., Plotti F., Pinelli C., Paderno M. C., Lopez S., Perrone A. M., Barra F., Guerrisi R., Brusadelli C., Cromi A., Ferrari D., Chiapp V., Signorelli M., Maggiore U. L. R., Ditto A., Palaia I., Ferrero S., De Iaco P., Angioli R., Panici P. B., Ghezzi F., Landoni F., Mueller M. D., and Raspagliesi F.

Abstract

Objective: Sentinel node mapping (SLN) has replaced lymphadenectomy for staging surgery in apparent early-stage low and intermediate risk endometrial cancer (EC). Only limited data about the adoption of SNM in high risk EC is still available. Here, we evaluate the outcomes of high-risk EC undergoing SNM (with or without back-up lymphadenectomy). Methods: This is a multi-institutional international retrospective study, evaluating data of high-risk (FIGO grade 3 endometrioid EC with myometrial invasion >50% and non-endometrioid histology) EC patients undergoing SNM followed by back-up lymphadenectomy and SNM alone. Results: Chart of consecutive 196 patients were evaluated. The study population included 83 and 113 patients with endometrioid and non-endometrioid EC, respectively. SNM alone and SNM followed by back-up lymphadenectomy were performed in 50 and 146 patients, respectively. Among patients having SNM alone, 14 (28%) were diagnosed with nodal disease. In the group of patients undergoing SNM plus back-up lymphadenectomy 34 (23.2%) were diagnosed with nodal disease via SNM. Back-up lymphadenectomy identified 2 (1%) additional patients with nodal disease (in the para-aortic area). Back-up lymphadenectomy allowed to remove adjunctive positive nodes in 16 (11%) patients. After the adoption of propensity-matched algorithm, we observed that patients undergoing SNM plus back-up lymphadenectomy experienced similar disease-free survival (p = 0.416, log-rank test) and overall survival (p = 0.940, log-rank test) than patients undergoing SLN alone. Conclusions: Although the small sample size, and the retrospective study design this study highlighted that type of nodal assessment did not impact survival outcomes in high-risk EC. Theoretically, back-up lymphadenectomy would be useful in improving the removal of positive nodes, but its therapeutic value remains controversial. Further prospective evidence is needed.

Published
2021

32. First-line treatment with olaparib for early stage BRCA-positive ovarian cancer: May it be possible? Hypothesis potentially generating a line of research

Author

Tomao, F, Boccia, S, Chirra, M, Palaia, I, Petrella, M, Di Donato, V, Colombo, N, Panici, P, Sassu, C, Tomao F., Boccia S. M., Chirra M., Palaia I., Petrella M. C., Di Donato V., Colombo N., Panici P. B., Sassu C. M., Tomao, F, Boccia, S, Chirra, M, Palaia, I, Petrella, M, Di Donato, V, Colombo, N, Panici, P, Sassu, C, Tomao F., Boccia S. M., Chirra M., Palaia I., Petrella M. C., Di Donato V., Colombo N., Panici P. B., and Sassu C. M.

Abstract

Olaparib is currently approved in maintenance treatment of advanced ovarian cancer after response to first-line chemotherapy for breast related cancer antigens (BRCA) mutated patients. The use of this agent is based on data from SOLO1 study that observed a decreased risk of disease progression or death and a median progression-free survival about 36 months longer in case of therapy with olaparib. However, this trial recruited only patients with advanced stage ovarian cancer. The aim of this review is to retrace the available data in order to clarify the potential efficacy and feasibility of olaparib administration in newly diagnosed epithelial ovarian cancer also in early stages.

Published
2020

34. Zebrafish, a novel key player for human risk assessment: latest advances on developmental neurotoxicity from an international consortium

Author

Sanz, C.M., Ibarra, J., Rubbini, D., Hsieh, J.-H., Ellis, L., Alzualde, A., Truong, L., Klüver, Nils, Muriana, A., Ryan, K., Behl, M., Molina, B., Legradi, J., Padilla, S., Woodland, C., Tanguay, R., Hill, B., Shafer, T., Sachana, M., Terriente, J., Di Donato, V., Schiavone, V., Hessel, E., Sanz, C.M., Ibarra, J., Rubbini, D., Hsieh, J.-H., Ellis, L., Alzualde, A., Truong, L., Klüver, Nils, Muriana, A., Ryan, K., Behl, M., Molina, B., Legradi, J., Padilla, S., Woodland, C., Tanguay, R., Hill, B., Shafer, T., Sachana, M., Terriente, J., Di Donato, V., Schiavone, V., and Hessel, E.

Abstract

no abstract

Published
2022

35. Evaluating long-term outcomes of three approaches to retroperitoneal staging in endometrial cancer

Author

Bogani, G, Di Donato, V, Papadia, A, Buda, A, Casarin, J, Multinu, F, Plotti, F, Cuccu, I, D'Auge, T, Gasparri, M, Pinelli, C, Perrone, A, Barra, F, Sorbi, F, Cromi, A, Di Martino, G, Palaia, I, Perniola, G, Ferrero, S, De Iaco, P, Perrone, C, Angioli, R, Luvero, D, Muzii, L, Ghezzi, F, Landoni, F, Mueller, M, Benedetti Panici, P, Raspagliesi, F, Bogani, Giorgio, Di Donato, Violante, Papadia, Andrea, Buda, Alessandro, Casarin, Jvan, Multinu, Francesco, Plotti, Francesco, Cuccu, Ilaria, D'Auge, Tullio Golia, Gasparri, Maria Luisa, Pinelli, Ciro, Perrone, Anna Myriam, Barra, Fabio, Sorbi, Flavia, Cromi, Antonella, Di Martino, Giampaolo, Palaia, Innocenza, Perniola, Giorgia, Ferrero, Simone, De Iaco, Pierandrea, Perrone, Chiara, Angioli, Roberto, Luvero, Daniela, Muzii, Ludovico, Ghezzi, Fabio, Landoni, Fabio, Mueller, Michael D, Benedetti Panici, Pierluigi, Raspagliesi, Francesco, Bogani, G, Di Donato, V, Papadia, A, Buda, A, Casarin, J, Multinu, F, Plotti, F, Cuccu, I, D'Auge, T, Gasparri, M, Pinelli, C, Perrone, A, Barra, F, Sorbi, F, Cromi, A, Di Martino, G, Palaia, I, Perniola, G, Ferrero, S, De Iaco, P, Perrone, C, Angioli, R, Luvero, D, Muzii, L, Ghezzi, F, Landoni, F, Mueller, M, Benedetti Panici, P, Raspagliesi, F, Bogani, Giorgio, Di Donato, Violante, Papadia, Andrea, Buda, Alessandro, Casarin, Jvan, Multinu, Francesco, Plotti, Francesco, Cuccu, Ilaria, D'Auge, Tullio Golia, Gasparri, Maria Luisa, Pinelli, Ciro, Perrone, Anna Myriam, Barra, Fabio, Sorbi, Flavia, Cromi, Antonella, Di Martino, Giampaolo, Palaia, Innocenza, Perniola, Giorgia, Ferrero, Simone, De Iaco, Pierandrea, Perrone, Chiara, Angioli, Roberto, Luvero, Daniela, Muzii, Ludovico, Ghezzi, Fabio, Landoni, Fabio, Mueller, Michael D, Benedetti Panici, Pierluigi, and Raspagliesi, Francesco

Abstract

Objective: Sentinel lymph node mapping (SNM) has gained popularity in managing apparent early-stage endometrial cancer (EC). Here, we evaluated the long-term survival of three different approaches of nodal assessment. Methods: This is a multi-institutional retrospective study evaluating long-term outcomes of EC patients having nodal assessment between 01/01/2006 and 12/31/2016. In order to reduce possible confounding factors, we applied a propensity-matched algorithm. Results: Overall, 940 patients meeting inclusion criteria were included in the study, of which 174 (18.5%), 187 (19.9%), and 579 (61.6%) underwent SNM, SNM followed by backup lymphadenectomy (LND) and LND alone, respectively. Applying a propensity score matching algorithm (1:1:2) we selected 500 patients, including 125 SNM, 125 SNM/backup LND, and 250 LND. Baseline characteristics of the study population were similar between groups. The prevalence of nodal disease was 14%, 16%, and 12% in patients having SNM, SNM/backup LND and LND, respectively. Overall, 19 (7.6%) patients were diagnosed with low volume nodal disease. The survival analysis comparing the three techniques did not show statistical differences in terms of disease-free (p = 0.750) and overall survival (p = 0.899). Similarly, the type of nodal assessment did not impact survival outcomes after stratification based on uterine risk factors. Conclusion: Our study highlighted that SNM provides similar long-term oncologic outcomes than LND.

Published
2022

36. Assessing the role of minimally invasive radical hysterectomy for early-stage cervical cancer

Author

Bogani, G, Di Donato, V, Muzii, L, Casarin, J, Ghezzi, F, Malzoni, M, Greggi, S, Landoni, F, Bazzurini, L, Zanagnolo, V, Multinu, F, Angioli, R, Plotti, F, Caruso, G, Fischetti, M, Ferrandina, G, Palaia, I, Benedetti Panici, P, Scambia, G, Raspagliesi, F, Bogani, Giorgio, Di Donato, Violante, Muzii, Ludovico, Casarin, Jvan, Ghezzi, Fabio, Malzoni, Mario, Greggi, Stefano, Landoni, Fabio, Bazzurini, Luca, Zanagnolo, Vanna, Multinu, Francesco, Angioli, Roberto, Plotti, Francesco, Caruso, Giuseppe, Fischetti, Margherita, Ferrandina, Gabriella, Palaia, Innocenza, Benedetti Panici, Pierluigi, Scambia, Giovanni, Raspagliesi, Francesco, Bogani, G, Di Donato, V, Muzii, L, Casarin, J, Ghezzi, F, Malzoni, M, Greggi, S, Landoni, F, Bazzurini, L, Zanagnolo, V, Multinu, F, Angioli, R, Plotti, F, Caruso, G, Fischetti, M, Ferrandina, G, Palaia, I, Benedetti Panici, P, Scambia, G, Raspagliesi, F, Bogani, Giorgio, Di Donato, Violante, Muzii, Ludovico, Casarin, Jvan, Ghezzi, Fabio, Malzoni, Mario, Greggi, Stefano, Landoni, Fabio, Bazzurini, Luca, Zanagnolo, Vanna, Multinu, Francesco, Angioli, Roberto, Plotti, Francesco, Caruso, Giuseppe, Fischetti, Margherita, Ferrandina, Gabriella, Palaia, Innocenza, Benedetti Panici, Pierluigi, Scambia, Giovanni, and Raspagliesi, Francesco

Abstract

Surgery is the mainstay of treatment in the management of early-stage cervical cancer. Until the publication of the Laparoscopic Approach to Cervical Cancer (LACC) trial, minimally invasive radical hysterectomy was the recommended approach to treat patients with early-stage disease. The results of the LACC trial questioned the adoption of minimally invasive surgery in cervical cancer. In comparison with the open approach, minimally invasive surgery correlated with worse disease-free and cancer-specific survival. Similarly, other retrospective studies highlighted this correlation, thus corroborating the results of the LACC trials. In the present review, we evaluated current evidence and further prospective of the adoption of minimally invasive radical hysterectomy in cervical cancer. Moreover, we sought to assess some unsolved issues regarding the role of minimally invasive surgery in early-stage cervical cancer patients.

Published
2022

37. Fertility-sparing treatment for serous borderline ovarian tumors with extra-ovarian invasive implants: Analysis from the MITO14 study database

Author

Falcone, F., Malzoni, M., Carnelli, M., Cormio, G., De Iaco, P., Di Donato, V., Ferrandina, Maria Gabriella, Raspagliesi, F., Sorio, R., Losito, N. S., Greggi, S., Ferrandina G. (ORCID:0000-0003-4672-4197), Falcone, F., Malzoni, M., Carnelli, M., Cormio, G., De Iaco, P., Di Donato, V., Ferrandina, Maria Gabriella, Raspagliesi, F., Sorio, R., Losito, N. S., Greggi, S., and Ferrandina G. (ORCID:0000-0003-4672-4197)

Abstract

Objective: Only 10–15% of serous borderline ovarian tumors (BOTs) with extra-ovarian disease have invasive implants, and conservative treatments have been rarely reported. The MITO14 is a multi-institutional retrospective study conducted with the aim of systematically collecting data from consecutive BOT patients. The present analysis reports the oncological and reproductive outcomes of women with serous BOT and invasive implants registered into the MITO14 database and conservatively treated between August 2002 and May 2019. Methods: Thirteen patients (FIGO2014 stage II–III serous BOT with invasive implants) were recruited. Primary and secondary endpoints were, respectively, recurrence and death rates, and pregnancy and live birth rates. Only patients undergoing fertility-sparing surgery (FSS) were included, while patients were excluded in case of: age > 45 years; second tumor(s) requiring therapy interfering with the treatment of BOT. Results: Median follow-up time from primary cytoreduction was 146 months (range 27–213 months). Eleven patients (84.6%) experienced at least one recurrence (median time to first relapse 17 months, range 4–190 months), all of these undergoing secondary surgery (FSS in 7). Five patients attempted to conceive: 3 achieved at least one pregnancy and 2 gave birth at least to a healthy child. At the end of the observation period, all patients were alive with no evidence of disease. Conclusions: Fertility-sparing treatment should be considered in a context of serous BOT with invasive implants. Despite the high rate of recurrence, FSS provides good chances of reproductive success without a negative impact on overall survival.

Published
2022

38. Characteristics and patterns of care of endometrial cancer before and during COVID-19 pandemic

Author

Bogani, G., Scambia, Giovanni, Cimmino, C., Fanfani, Francesco, Costantini, Barbara, Loverro, Matteo, Ferrandina, Maria Gabriella, Landoni, F., Bazzurini, L., Grassi, T., Vitobello, D., Siesto, G., Perrone, A. M., Zanagnolo, V., De Iaco, P., Multinu, F., Ghezzi, F., Casarin, J., Berretta, R., Capozzi, V. A., Zupi, E., Centini, G., Pellegrino, Antonio Agostino, Corso, S., Stevenazzi, G., Montoli, Stefano, Boschi, A. C., Comerci, Gianluca, Greco, Pierfrancesco, Martinello, R., Sopracordevole, F., Giorda, G., Simoncini, T., Caretto, M., Sartori, E., Ferrari, F., Cianci, A., Sarpietro, G., Matarazzo, M. G., Zullo, F., Bifulco, G., Morelli, Marco, Ferrero, A., Biglia, N., Barra, F., Ferrero, S., Maggiore, U. L. R., Cianci, Stefano, Chiantera, V., Ercoli, Alfredo, Sozzi, G., Martoccia, A., Schettini, Sergio Crescenzo, Orlando, T., Cannone, F. G., Ettore, G., Puppo, A., Borghese, M., Martinelli, C., Muzii, L., Di Donato, V., Driul, L., Restaino, S., Bergamini, A., Candotti, G., Bocciolone, L., Plotti, F., Angioli, R., Mantovani, G., Ceccaroni, Marcello, Cassani, C., Dominoni, M., Giambanco, L., Amodeo, Silvia, Leo, Maria Laura, Thomasset, R., Raimondo, D., Seracchioli, R., Malzoni, M., Gorlero, F., Di Luca, M., Busato, E., Kilzie, S., Dell'Acqua, Antonio, Scarfone, G., Vercellini, P., Petrillo, Marco, Dessole, S., Capobianco, G., Ciavattini, A., Delli Carpini, G., Giannella, L., Mereu, L., Tateo, S., Sorbi, F., Fambrini, M., Cicogna, S., Romano, Federica, Ricci, Giuseppe, Trojano, G., Consonni, R., Cantaluppi, S., Lippolis, A., Tinelli, R., D'Ippolito, G., Aguzzoli, L., Mandato, V. D., Palomba, S., Calandra, D., Rosati, M., Gallo, C., Surico, D., Remorgida, V., Ruscitto, F., Beretta, P., Panici, P. B., Raspagliesi, F., Scambia G. (ORCID:0000-0003-2758-1063), Fanfani F. (ORCID:0000-0003-1991-7284), Costantini B., Loverro M., Ferrandina G. (ORCID:0000-0003-4672-4197), Pellegrino A., Montoli S., Comerci G., Greco P., Morelli M., Cianci S., Ercoli A., Schettini S., Ceccaroni M., Amodeo S., Leo L., Dell'acqua A. (ORCID:0000-0002-8697-3115), Petrillo M., Romano F., Ricci G., Bogani, G., Scambia, Giovanni, Cimmino, C., Fanfani, Francesco, Costantini, Barbara, Loverro, Matteo, Ferrandina, Maria Gabriella, Landoni, F., Bazzurini, L., Grassi, T., Vitobello, D., Siesto, G., Perrone, A. M., Zanagnolo, V., De Iaco, P., Multinu, F., Ghezzi, F., Casarin, J., Berretta, R., Capozzi, V. A., Zupi, E., Centini, G., Pellegrino, Antonio Agostino, Corso, S., Stevenazzi, G., Montoli, Stefano, Boschi, A. C., Comerci, Gianluca, Greco, Pierfrancesco, Martinello, R., Sopracordevole, F., Giorda, G., Simoncini, T., Caretto, M., Sartori, E., Ferrari, F., Cianci, A., Sarpietro, G., Matarazzo, M. G., Zullo, F., Bifulco, G., Morelli, Marco, Ferrero, A., Biglia, N., Barra, F., Ferrero, S., Maggiore, U. L. R., Cianci, Stefano, Chiantera, V., Ercoli, Alfredo, Sozzi, G., Martoccia, A., Schettini, Sergio Crescenzo, Orlando, T., Cannone, F. G., Ettore, G., Puppo, A., Borghese, M., Martinelli, C., Muzii, L., Di Donato, V., Driul, L., Restaino, S., Bergamini, A., Candotti, G., Bocciolone, L., Plotti, F., Angioli, R., Mantovani, G., Ceccaroni, Marcello, Cassani, C., Dominoni, M., Giambanco, L., Amodeo, Silvia, Leo, Maria Laura, Thomasset, R., Raimondo, D., Seracchioli, R., Malzoni, M., Gorlero, F., Di Luca, M., Busato, E., Kilzie, S., Dell'Acqua, Antonio, Scarfone, G., Vercellini, P., Petrillo, Marco, Dessole, S., Capobianco, G., Ciavattini, A., Delli Carpini, G., Giannella, L., Mereu, L., Tateo, S., Sorbi, F., Fambrini, M., Cicogna, S., Romano, Federica, Ricci, Giuseppe, Trojano, G., Consonni, R., Cantaluppi, S., Lippolis, A., Tinelli, R., D'Ippolito, G., Aguzzoli, L., Mandato, V. D., Palomba, S., Calandra, D., Rosati, M., Gallo, C., Surico, D., Remorgida, V., Ruscitto, F., Beretta, P., Panici, P. B., Raspagliesi, F., Scambia G. (ORCID:0000-0003-2758-1063), Fanfani F. (ORCID:0000-0003-1991-7284), Costantini B., Loverro M., Ferrandina G. (ORCID:0000-0003-4672-4197), Pellegrino A., Montoli S., Comerci G., Greco P., Morelli M., Cianci S., Ercoli A., Schettini S., Ceccaroni M., Amodeo S., Leo L., Dell'acqua A. (ORCID:0000-0002-8697-3115), Petrillo M., Romano F., and Ricci G.

Abstract

Objective: Coronavirus disease 2019 (COVID-19) outbreak has correlated with the disruption of screening activities and diagnostic assessments. Endometrial cancer (EC) is one of the most common gynecological malignancies and it is often detected at an early stage, because it frequently produces symptoms. Here, we aim to investigate the impact of COVID-19 outbreak on patterns of presentation and treatment of EC patients. Methods: This is a retrospective study involving 54 centers in Italy. We evaluated patterns of presentation and treatment of EC patients before (period 1: March 1, 2019 to February 29, 2020) and during (period 2: April 1, 2020 to March 31, 2021) the COVID-19 outbreak. Results: Medical records of 5,164 EC patients have been retrieved: 2,718 and 2,446 women treated in period 1 and period 2, respectively. Surgery was the mainstay of treatment in both periods (p=0.356). Nodal assessment was omitted in 689 (27.3%) and 484 (21.2%) patients treated in period 1 and 2, respectively (p<0.001). While, the prevalence of patients undergoing sentinel node mapping (with or without backup lymphadenectomy) has increased during the COVID-19 pandemic (46.7% in period 1 vs. 52.8% in period 2; p<0.001). Overall, 1,280 (50.4%) and 1,021 (44.7%) patients had no adjuvant therapy in period 1 and 2, respectively (p<0.001). Adjuvant therapy use has increased during COVID-19 pandemic (p<0.001). Conclusion: Our data suggest that the COVID-19 pandemic had a significant impact on the characteristics and patterns of care of EC patients. These findings highlight the need to implement healthcare services during the pandemic.

Published
2022

39. Characteristics and patterns of care of endometrial cancer before and during COVID-19 pandemic

Author

Bogani, G, Scambia, G, Cimmino, C, Fanfani, F, Costantini, B, Loverro, M, Ferrandina, G, Landoni, F, Bazzurini, L, Grassi, T, Vitobello, D, Siesto, G, Perrone, A, Zanagnolo, V, De Iaco, P, Multinu, F, Ghezzi, F, Casarin, J, Berretta, R, Capozzi, V, Zupi, E, Centini, G, Pellegrino, A, Corso, S, Stevenazzi, G, Montoli, S, Boschi, A, Comerci, G, Greco, P, Martinello, R, Sopracordevole, F, Giorda, G, Simoncini, T, Caretto, M, Sartori, E, Ferrari, F, Cianci, A, Sarpietro, G, Matarazzo, M, Zullo, F, Bifulco, G, Morelli, M, Ferrero, A, Biglia, N, Barra, F, Ferrero, S, Leone Roberti Maggiore, U, Cianci, S, Chiantera, V, Ercoli, A, Sozzi, G, Martoccia, A, Schettini, S, Orlando, T, Cannone, F, Ettore, G, Puppo, A, Borghese, M, Martinelli, C, Muzii, L, Di Donato, V, Driul, L, Restaino, S, Bergamini, A, Candotti, G, Bocciolone, L, Plotti, F, Angioli, R, Mantovani, G, Ceccaroni, M, Cassani, C, Dominoni, M, Giambanco, L, Amodeo, S, Leo, L, Thomasset, R, Raimondo, D, Seracchioli, R, Malzoni, M, Gorlero, F, Di Luca, M, Busato, E, Kilzie, S, Dell'Acqua, A, Scarfone, G, Vercellini, P, Petrillo, M, Dessole, S, Capobianco, G, Ciavattini, A, Delli Carpini, G, Giannella, L, Mereu, L, Tateo, S, Sorbi, F, Fambrini, M, Cicogna, S, Romano, F, Ricci, G, Trojano, G, Consonni, R, Cantaluppi, S, Lippolis, A, Tinelli, R, D'Ippolito, G, Aguzzoli, L, Mandato, V, Palomba, S, Calandra, D, Rosati, M, Gallo, C, Surico, D, Remorgida, V, Ruscitto, F, Beretta, P, Benedetti Panici, P, Raspagliesi, F, Bogani, Giorgio, Scambia, Giovanni, Cimmino, Chiara, Fanfani, Francesco, Costantini, Barbara, Loverro, Matteo, Ferrandina, Gabriella, Landoni, Fabio, Bazzurini, Luca, Grassi, Tommaso, Vitobello, Domenico, Siesto, Gabriele, Perrone, Anna Myriam, Zanagnolo, Vanna, De Iaco, Pierandrea, Multinu, Francesco, Ghezzi, Fabio, Casarin, Jvan, Berretta, Roberto, Capozzi, Vito A, Zupi, Errico, Centini, Gabriele, Pellegrino, Antonio, Corso, Silvia, Stevenazzi, Guido, Montoli, Serena, Boschi, Anna Chiara, Comerci, Giuseppe, Greco, Pantaleo, Martinello, Ruby, Sopracordevole, Francesco, Giorda, Giorgio, Simoncini, Tommaso, Caretto, Marta, Sartori, Enrico, Ferrari, Federico, Cianci, Antonio, Sarpietro, Giuseppe, Matarazzo, Maria Grazia, Zullo, Fulvio, Bifulco, Giuseppe, Morelli, Michele, Ferrero, Annamaria, Biglia, Nicoletta, Barra, Fabio, Ferrero, Simone, Leone Roberti Maggiore, Umberto, Cianci, Stefano, Chiantera, Vito, Ercoli, Alfredo, Sozzi, Giulio, Martoccia, Angela, Schettini, Sergio, Orlando, Teresa, Cannone, Francesco G, Ettore, Giuseppe, Puppo, Andrea, Borghese, Martina, Martinelli, Canio, Muzii, Ludovico, Di Donato, Violante, Driul, Lorenza, Restaino, Stefano, Bergamini, Alice, Candotti, Giorgio, Bocciolone, Luca, Plotti, Francesco, Angioli, Roberto, Mantovani, Giulia, Ceccaroni, Marcello, Cassani, Chiara, Dominoni, Mattia, Giambanco, Laura, Amodeo, Silvia, Leo, Livio, Thomasset, Raphael, Raimondo, Diego, Seracchioli, Renato, Malzoni, Mario, Gorlero, Franco, Di Luca, Martina, Busato, Enrico, Kilzie, Sami, Dell'Acqua, Andrea, Scarfone, Giovanna, Vercellini, Paolo, Petrillo, Marco, Dessole, Salvatore, Capobianco, Giampiero, Ciavattini, Andrea, Delli Carpini, Giovanni, Giannella, Luca, Mereu, Liliana, Tateo, Saverio, Sorbi, Flavia, Fambrini, Massimiliano, Cicogna, Stefania, Romano, Federico, Ricci, Giuseppe, Trojano, Giuseppe, Consonni, Roberto, Cantaluppi, Simona, Lippolis, Antonio, Tinelli, Raffaele, D'Ippolito, Giovanni, Aguzzoli, Lorenzo, Mandato, Vincenzo D, Palomba, Stefano, Calandra, Davide, Rosati, Maurizio, Gallo, Cinzia, Surico, Daniela, Remorgida, Valentino, Ruscitto, Francesco, Beretta, Paolo, Benedetti Panici, Pierluigi, Raspagliesi, Francesco, Bogani, G, Scambia, G, Cimmino, C, Fanfani, F, Costantini, B, Loverro, M, Ferrandina, G, Landoni, F, Bazzurini, L, Grassi, T, Vitobello, D, Siesto, G, Perrone, A, Zanagnolo, V, De Iaco, P, Multinu, F, Ghezzi, F, Casarin, J, Berretta, R, Capozzi, V, Zupi, E, Centini, G, Pellegrino, A, Corso, S, Stevenazzi, G, Montoli, S, Boschi, A, Comerci, G, Greco, P, Martinello, R, Sopracordevole, F, Giorda, G, Simoncini, T, Caretto, M, Sartori, E, Ferrari, F, Cianci, A, Sarpietro, G, Matarazzo, M, Zullo, F, Bifulco, G, Morelli, M, Ferrero, A, Biglia, N, Barra, F, Ferrero, S, Leone Roberti Maggiore, U, Cianci, S, Chiantera, V, Ercoli, A, Sozzi, G, Martoccia, A, Schettini, S, Orlando, T, Cannone, F, Ettore, G, Puppo, A, Borghese, M, Martinelli, C, Muzii, L, Di Donato, V, Driul, L, Restaino, S, Bergamini, A, Candotti, G, Bocciolone, L, Plotti, F, Angioli, R, Mantovani, G, Ceccaroni, M, Cassani, C, Dominoni, M, Giambanco, L, Amodeo, S, Leo, L, Thomasset, R, Raimondo, D, Seracchioli, R, Malzoni, M, Gorlero, F, Di Luca, M, Busato, E, Kilzie, S, Dell'Acqua, A, Scarfone, G, Vercellini, P, Petrillo, M, Dessole, S, Capobianco, G, Ciavattini, A, Delli Carpini, G, Giannella, L, Mereu, L, Tateo, S, Sorbi, F, Fambrini, M, Cicogna, S, Romano, F, Ricci, G, Trojano, G, Consonni, R, Cantaluppi, S, Lippolis, A, Tinelli, R, D'Ippolito, G, Aguzzoli, L, Mandato, V, Palomba, S, Calandra, D, Rosati, M, Gallo, C, Surico, D, Remorgida, V, Ruscitto, F, Beretta, P, Benedetti Panici, P, Raspagliesi, F, Bogani, Giorgio, Scambia, Giovanni, Cimmino, Chiara, Fanfani, Francesco, Costantini, Barbara, Loverro, Matteo, Ferrandina, Gabriella, Landoni, Fabio, Bazzurini, Luca, Grassi, Tommaso, Vitobello, Domenico, Siesto, Gabriele, Perrone, Anna Myriam, Zanagnolo, Vanna, De Iaco, Pierandrea, Multinu, Francesco, Ghezzi, Fabio, Casarin, Jvan, Berretta, Roberto, Capozzi, Vito A, Zupi, Errico, Centini, Gabriele, Pellegrino, Antonio, Corso, Silvia, Stevenazzi, Guido, Montoli, Serena, Boschi, Anna Chiara, Comerci, Giuseppe, Greco, Pantaleo, Martinello, Ruby, Sopracordevole, Francesco, Giorda, Giorgio, Simoncini, Tommaso, Caretto, Marta, Sartori, Enrico, Ferrari, Federico, Cianci, Antonio, Sarpietro, Giuseppe, Matarazzo, Maria Grazia, Zullo, Fulvio, Bifulco, Giuseppe, Morelli, Michele, Ferrero, Annamaria, Biglia, Nicoletta, Barra, Fabio, Ferrero, Simone, Leone Roberti Maggiore, Umberto, Cianci, Stefano, Chiantera, Vito, Ercoli, Alfredo, Sozzi, Giulio, Martoccia, Angela, Schettini, Sergio, Orlando, Teresa, Cannone, Francesco G, Ettore, Giuseppe, Puppo, Andrea, Borghese, Martina, Martinelli, Canio, Muzii, Ludovico, Di Donato, Violante, Driul, Lorenza, Restaino, Stefano, Bergamini, Alice, Candotti, Giorgio, Bocciolone, Luca, Plotti, Francesco, Angioli, Roberto, Mantovani, Giulia, Ceccaroni, Marcello, Cassani, Chiara, Dominoni, Mattia, Giambanco, Laura, Amodeo, Silvia, Leo, Livio, Thomasset, Raphael, Raimondo, Diego, Seracchioli, Renato, Malzoni, Mario, Gorlero, Franco, Di Luca, Martina, Busato, Enrico, Kilzie, Sami, Dell'Acqua, Andrea, Scarfone, Giovanna, Vercellini, Paolo, Petrillo, Marco, Dessole, Salvatore, Capobianco, Giampiero, Ciavattini, Andrea, Delli Carpini, Giovanni, Giannella, Luca, Mereu, Liliana, Tateo, Saverio, Sorbi, Flavia, Fambrini, Massimiliano, Cicogna, Stefania, Romano, Federico, Ricci, Giuseppe, Trojano, Giuseppe, Consonni, Roberto, Cantaluppi, Simona, Lippolis, Antonio, Tinelli, Raffaele, D'Ippolito, Giovanni, Aguzzoli, Lorenzo, Mandato, Vincenzo D, Palomba, Stefano, Calandra, Davide, Rosati, Maurizio, Gallo, Cinzia, Surico, Daniela, Remorgida, Valentino, Ruscitto, Francesco, Beretta, Paolo, Benedetti Panici, Pierluigi, and Raspagliesi, Francesco

Abstract

Objective: Coronavirus disease 2019 (COVID-19) outbreak has correlated with the disruption of screening activities and diagnostic assessments. Endometrial cancer (EC) is one of the most common gynecological malignancies and it is often detected at an early stage, because it frequently produces symptoms. Here, we aim to investigate the impact of COVID-19 outbreak on patterns of presentation and treatment of EC patients. Methods: This is a retrospective study involving 54 centers in Italy. We evaluated patterns of presentation and treatment of EC patients before (period 1: March 1, 2019 to February 29, 2020) and during (period 2: April 1, 2020 to March 31, 2021) the COVID-19 outbreak. Results: Medical records of 5,164 EC patients have been retrieved: 2,718 and 2,446 women treated in period 1 and period 2, respectively. Surgery was the mainstay of treatment in both periods (p=0.356). Nodal assessment was omitted in 689 (27.3%) and 484 (21.2%) patients treated in period 1 and 2, respectively (p<0.001). While, the prevalence of patients undergoing sentinel node mapping (with or without backup lymphadenectomy) has increased during the COVID-19 pandemic (46.7% in period 1 vs. 52.8% in period 2; p<0.001). Overall, 1,280 (50.4%) and 1,021 (44.7%) patients had no adjuvant therapy in period 1 and 2, respectively (p<0.001). Adjuvant therapy use has increased during COVID-19 pandemic (p<0.001). Conclusion: Our data suggest that the COVID-19 pandemic had a significant impact on the characteristics and patterns of care of EC patients. These findings highlight the need to implement healthcare services during the pandemic.

Published
2022

44. EPV140/#62 Survival outcomes in endometrial cancer patients having lymphadenectomy, sentinel node mapping plus back-up lymphadenectomy and sentinel node mapping alone

Author

Bogani, G, primary, Ghezzi, F, additional, Angioli, R, additional, Papadia, A, additional, Buda, A, additional, Di Donato, V, additional, Plotti, F, additional, De Iaco, P, additional, Perrone, AM, additional, Ferrero, S, additional, Roberti Maggiore, U Leone, additional, Gasparri, ML, additional, Casarin, J, additional, Muzii, L, additional, Mueller, M, additional, Malzoni, M, additional, Landoni, F, additional, Benedetti Panici, P, additional, and Raspagliesi, F, additional

Published
2021
Full Text
View/download PDF

45. Lymphadenectomy, Sentinel Node Mapping Plus Backup Lymphadenectomy and Sentinel Node Mapping Alone in Endometrial Cancer

Author

Bogani, G., primary, Ghezzi, F., additional, Malzoni, M., additional, di Donato, V., additional, Casarin, J., additional, Ferrero, S., additional, Angioli, R., additional, Plotti, F., additional, Muzii, L., additional, De Iaco, P., additional, Perrone, A.M., additional, Papadia, A., additional, Gasparri, M.L., additional, Buda, A., additional, Landoni, F., additional, Mueller, M.D., additional, Panici, P. Benedetti, additional, and Raspagliesi, F., additional

Published
2021
Full Text
View/download PDF

46. Diet and Chemotherapy: The Effects of Fasting and Ketogenic Diet on Cancer Treatment

Author

Plotti, F., Terranova, C., Luvero, D., Bartolone, M., Messina, G., Feole, L., Cianci, S., Scaletta, G., Marchetti, C., Di Donato, V., Fagotti, A., Scambia, G., Benedetti Panici, P., Angioli, R., Cianci S., Scaletta G., Marchetti C. (ORCID:0000-0001-7098-8956), Fagotti A. (ORCID:0000-0001-5579-335X), Scambia G. (ORCID:0000-0003-2758-1063), Plotti, F., Terranova, C., Luvero, D., Bartolone, M., Messina, G., Feole, L., Cianci, S., Scaletta, G., Marchetti, C., Di Donato, V., Fagotti, A., Scambia, G., Benedetti Panici, P., Angioli, R., Cianci S., Scaletta G., Marchetti C. (ORCID:0000-0001-7098-8956), Fagotti A. (ORCID:0000-0001-5579-335X), and Scambia G. (ORCID:0000-0003-2758-1063)

Abstract

Introduction: Diet may influence various aspects of human health. In fact, it is well known that diet can favour or not the development of various human pathologies, like diabetes, hypertension, and hypercholesterolaemia. Interestingly, diet has an influence in cancer development too (e.g., this relation has been studied for pancreatic, colonic, gastric, and breast cancers). Between the mechanisms that could explain this relation, there is epigenetic. In fact, thanks to epigenetic reprogramming, certain substances introduced with diet could affect gene expression, especially of those genes involved in cells' proliferation and growth. In recent years, some studies have been published about the role that diet could have on chemotherapy outcome. Especially, various studies have analysed the effects of fasting and ketogenic diet (KD) during chemotherapy. The aim of this study is to summarize scientific evidences about diet and its effects on chemotherapy on humans and to better understand if these approaches deserve to be further investigated and might be suitable and beneficial during cancer treatment. Materials and Methods: We performed an electronic literature search of the PubMed database, using the combination of following terms: "fasting"or "ketogenic"with "chemotherapy,""cancer treatment."We included studies on humans about fasting and KD during chemotherapy, excluding reviews, case series including <10 patients, studies conducted on animals or limited to radiotherapy treatment, and studies that were mostly about molecular mechanisms. Results/Discussion In our analysis we included 4 studies (1 randomized controlled trial, 1 retrospective study, and 2 prospective pilot studies) about KD and 4 studies (1 prospective cohort study, 1 case series report, and 2 randomized trials) about fasting during oncological treatments. Authors suggested an improvement of quality of life (QoL) and fatigue in patients under chemotherapy, especially in the 8 days after chemotherap

Published
2020

48. 23 Impact of COVID-19 in gynecologic oncology: a nationwide Italian survey

Author

Bogani, G, primary, Apolone, G, additional, Ditto, A, additional, Scambia, G, additional, Benedetti Panici, P, additional, Angioli, R, additional, Pignata, S, additional, Greggi, S, additional, Scollo, P, additional, Mezzanzanica, D, additional, Franchi, M, additional, Di Donato, V, additional, Valabrega, G, additional, Ferrandina, G, additional, Palaia, I, additional, Bergamini, A, additional, Bocciolone, L, additional, Savarese, A, additional, Ghezzi, F, additional, Casarin, J, additional, Trojano, V, additional, Chinatera, V, additional, Giorda, G, additional, Malzoni, M, additional, Salerno, G, additional, Sartori, E, additional, Testa, A, additional, Zannoni, GF, additional, Zullo, F, additional, Vizza, E, additional, Trojano, G, additional, Chiantera, A, additional, and Raspagliesi, F, additional

Published
2020
Full Text
View/download PDF

50. Role of intraperitoneal chemotherapy in ovarian cancer in the platinum-taxane-based era: A meta-analysis

Author

Marchetti, Claudia, De Felice, F., Perniola, G., Palaia, I., Musella, A., Di Donato, V., Cascialli, G., Muzii, L., Tombolini, V., Benedetti Panici, P., Marchetti C. (ORCID:0000-0001-7098-8956), Marchetti, Claudia, De Felice, F., Perniola, G., Palaia, I., Musella, A., Di Donato, V., Cascialli, G., Muzii, L., Tombolini, V., Benedetti Panici, P., and Marchetti C. (ORCID:0000-0001-7098-8956)

Abstract

Purpose: Intravenous (IV) chemotherapy has been compared with intraperitoneal (IP) chemotherapy in randomized clinical trials in advanced ovarian cancer (OC). The aim of this meta-analysis was to evaluate efficacy and toxicity of IV and IP and identify differences in outcomes. Methods: The preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement was applied. Random-effects models were used. Primary endpoint was progression-free survival (PFS). Secondary endpoints were overall survival (OS) and the proportion of patients with grade ≥2 acute toxicity. Results: Four randomized clinical trials representing 2461 patients were identified. The hazard ratio (HR) of PFS was 0.88 (95% CI 0.80–0.98; p = 0.01, I 2 = 24%) in favor of IP chemotherapy. IP chemotherapy was also associated with significant OS improvement compared with IV chemotherapy, with HR of 0.79 (95% CI 0.67–0.92; p = 0.003, I 2 = 0%). Globally, grade ≥2 toxicities were reduced with IV chemotherapy. Conclusion: This meta-analysis shows the superiority of IP chemotherapy over IV infusion in terms of clinical outcomes but toxicity rates. Its precise role in the management of advanced OC remains to be determined.

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results